[Top-Tier Insight] Up to $2.6 Billion! Weight-Loss Drug Licensed to Novo Nordisk — Hengrui Medicine (01276.HK) Stock Rises

On September 29, spurred by the positive catalyst of a major overseas licensing deal for an innovative drug, Hengrui Medicine’s stock experienced notable price movement. In Hong Kong, Hengrui Medicine (01276.HK) surged over 5% in the afternoon before retreating slightly; as of press time, its share price rose 2.5% to HK$45.88 per share. Concurrently, its A-share listing (600276.SH) climbed 2.56% to RMB 45.61 per share—both markets responded positively to this business development (BD) collaboration. News-wise, on the afternoon of September 29, Hengrui Medicine announced it had entered into a license agreement with Novo Nordisk A/S, a global leader in metabolic disease therapeutics, granting an exclusive, paid license for HRS-1596—a self-developed, orally administered GLP-1/GIP dual-receptor agonist with potential for once-weekly dosing. Under the agreement, Novo Nordisk acquires exclusive rights to develop, manufacture, and commercialize HRS-1596 globally outside Greater China, while Hengrui retains full rights across Greater China. The transaction carries a potential total value of up to USD 2.6 billion, comprising a USD 300 million upfront payment and subsequent milestone payments tied to development, regulatory approval, and commercialization phases. Additionally, Hengrui is entitled to royalties based on net sales of the product in the licensed territories. HRS-1596 is a self-developed metabolic candidate drug from Hengrui, designed to treat obesity, type 2 diabetes, and other metabolic disorders through multiple pharmacological mechanisms—including appetite suppression, enhanced insulin secretion, and improved insulin sensitivity—delivered via a once-weekly oral regimen. Compared with mainstream injectable formulations, this oral modality holds promise for significantly improving patient adherence. Currently, HRS-1596 remains in Phase I clinical trials; further progress in overseas clinical development and regulatory approval remains uncertain, and achievement of milestone payments depends entirely on actual future R&D and commercialization outcomes.

Accelerating Global Expansion! Hengrui Medicine Licenses Oral GLP-1/GIP Weight-Loss Drug to Novo Nordisk, Potential Deal Value Up to $2.6 Billion

Hengrui Medicine has licensed its self-developed oral GLP-1/GIP dual-receptor agonist, HRS-1596, to Novo Nordisk—the global leader in weight-loss therapeutics—in a deal with a potential total value of up to USD 2.6 billion. This marks another milestone in Chinese innovative pharmaceutical companies’ global expansion into the weight-loss therapeutic arena. On September 29, Hengrui Medicine announced that it had signed a license agreement with Novo Nordisk for the HRS-1596 program. Per the agreement, Novo Nordisk obtains exclusive global rights—excluding Greater China—to develop, manufacture, and commercialize HRS-1596. The deal includes a USD 300 million upfront payment and milestone payments of up to USD 2.3 billion tied to development, regulatory approval, and commercialization, bringing the potential total transaction value to USD 2.6 billion. In addition, Hengrui will receive royalties based on net sales of HRS-1596 in the licensed territories. Following the announcement, Hengrui Medicine’s stock price surged sharply, briefly rising over 3%. HRS-1596: Once-weekly oral dosing, still in early-stage clinical development HRS-1596 is a self-developed GLP-1/GIP dual-receptor agonist from Hengrui, aiming to achieve weight loss and glycemic control through multiple mechanisms—including appetite suppression, stimulation of insulin secretion, and improvement of insulin sensitivity—making it a promising candidate for treating obesity, type 2 diabetes, and other metabolic diseases. Its key differentiating advantage lies in its route of administration: HRS-1596 is designed for once-weekly oral dosing, which could substantially reduce dosing frequency and markedly improve patient adherence compared with existing injectable therapies. Hengrui has already received regulatory approval in China to initiate Phase I clinical trials of HRS-1596 for weight management and type 2 diabetes; overall, the product remains in early-stage development. In its announcement, Hengrui cautioned that drug development—from preclinical research and clinical trial applications to final manufacturing and market launch—is a lengthy, multi-stage process. The ultimate regulatory approval and commercialization of HRS-1596 overseas remain uncertain, and the milestone payments stipulated in the agreement are contingent upon fulfillment of specific conditions; therefore, the final amounts remain subject to change.

China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

1 day ago

Jiangsu Hengrui Pharmaceuticals has licensed global rights to its weight-management drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6 billion, including a $300 million upfront fee.

reuters

2026-09-28

China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

FAQ